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The tumour microenvironment is believed to be involved in development, growth, metastasis, and therapy resistance of many
cancers. Here we show survivin, a member of the inhibitor of apoptosis protein (IAP) family, implicated in apoptosis inhibition and the
regulation of mitosis in cancer cells, exists in a novel extracellular pool in tumour cells. Furthermore, we have constructed stable cell
lines that provide the extracellular pool with either wild-type survivin (Surv-WT) or the previously described dominant-negative
mutant survivin (Surv-T34A), which has proven pro-apoptotic effects in cancer cells but not in normal proliferating cells. Cancer cells
grown in conditioned medium (CM) taken from Surv-WT cells absorbed survivin and experienced enhanced protection against
genotoxic stresses. These cells also exhibited an increased replicative and metastatic potential, suggesting that survivin in the tumour
microenvironment may be directly associated with malignant progression, further supporting survivin’s function in tumourigenesis.
Alternatively, cancer cells grown in CM taken from the Surv-T34A cells began to apoptose through a caspase-2- and caspase-9-
dependent pathway that was further enhanced by the addition of other chemo- and radiotherapeutic modalities. Together our
findings suggest a novel microenvironmental function for survivin in the control of cancer aggressiveness and spread, and should result
in the genesis of additional cancer treatment modalities.
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The complexity and heterogeneity of the tumour microenviron-
ment (Tredan et al, 2007) is believed to have an important function
in the development, growth, metastasis, and therapy resistance of
many cancers (Ohtani, 1998). The tumour is not merely a single
genotype-containing clonal mass but a community of hetero-
geneous cancer cells and stromal cells embedded in an extra-
cellular matrix and nourished by vascular and fibroblast cell
networks (Aznavoorian et al, 1990).
The multifunctional protein survivin controls diverse cellular
functions, including surveillance checkpoints, suppression of cell
death, the regulation of mitosis, and the adaptation to unfavour-
able environments (Li et al, 1998; Altieri, 2003, 2006). The
suppression of cell death activities and baculovirus inhibitor of
apoptosis protein (IAP) repeat (BIR) domain characterises
survivin as a member of the IAP family (Ambrosini et al, 1997).
However, survivin’s lack of a C-terminal RING finger domain and
a caspase recruitment domain (Deveraux and Reed, 1999) makes it
structurally unique among the mammalian IAPs. The multifaceted
functionality of survivin is still being intensely scrutinised,
although it appears that protein compartmentalisation may be
important. Survivin was recently shown to colocalise in the
mitochondria, where it abolishes tumour cell apoptosis and
promotes tumourigenesis in immunocompromised animals (Dohi
et al, 2004). Survivin may therefore possess a function in apoptosis
similar to the pro-apoptotic Bcl-2 family proteins. Furthermore,
survivin has been also found in the nucleus and cytosol where the
implication is that it has functions in mitosis regulation and
apoptosis inhibition, respectively (Fortugno et al, 2002). Survivin
is expressed in most common human cancers and although
present during embryonic and foetal development, it is undetect-
able in a variety of adult tissues (Adida et al, 1998) and for this
reason it is currently recognised as an important anticancer target
(Fukuda and Pelus, 2006). For this purpose, multiple strategies
have been successfully investigated, including the molecular
antagonists such as antisense oligos, RNA inhibition, dominant-
negative mutants, survivin-specific cytolytic T cells, a non-
phosphorylatable survivin mutant Thr
34-Ala (T34A), and most
recently, binding interface mimetics (Olie et al, 2000; Andersen
et al, 2001; Grossman et al, 2001; Kanwar et al, 2001; Mesri et al,
2001; Wall et al, 2003; Plescia et al, 2005).
In the present study, we investigate whether extracellular
compartmentalisation of survivin participates in the cytoprotec-
tion, tumourigenesis, and enhanced metastasis encountered in the
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stumour microenvironment. We have identified a novel pool of
survivin, localised extracellularly, that is readily taken up by cancer
cells but not by normal stromal cells. Furthermore, cancer cells
that absorb survivin show enhanced growth patterns and are more
resistant to genotoxic stress than controls containing only
endogenous levels of survivin. Further investigations to define
uptake-induced phenotypes of the apoptosis inducing non-
phosphorylatable survivin-mutant (T34A) have shown a caspase-
dependent enhancement of chemotherapy-induced cell death,
in vitro.
MATERIALS AND METHODS
Cell lines and cultures
Cervical carcinoma (HeLa and HeLa-S), osteosarcoma (U2OS and
SaOS2), pancreatic carcinoma (Panc1, Capan1, and Capan2),
prostate carcinoma (PC3, DU-145, and RWPE-2), and breast
carcinoma (MCF-7, HCC 1806) cell lines were obtained from the
American Type Culture Collection (ATCC) as were the human
normal prostate stromal cells (PrSC). The acute monocytic
leukaemia cell lines (MOLM-14 and MV4-11) were a kind gift
from CS Chen (Loma Linda University). Normal prostate epithelial
cells (PrEC) were obtained from Clonetics-BioWhittaker
(Walkersville, MD, USA) and cultured in PrEMB medium
(Clonetics-BioWhittaker). The normal human bone marrow
stromal (HBMS) cells were a generous gift of Kimberly Payne
(Loma Linda University). Stromal cells were isolated and
propagated as previously described (Hao et al, 1995) from adult
human bone marrow that was purchased from Poietics Cell
Systems (Lonza Walkersville Inc., Gaithersburg, MD, USA).
Human peripheral blood mononuclear cells were isolated from a
peripheral blood draw using Ficoll-Hypaque (GE Healthcare Bio-
Sciences Corp., Piscataway, NJ, USA) as has been previously
described (Wang et al, 1984). The use of all human tissues was
reviewed and approved by the institutional review board at Loma
Linda University with informed written consent obtained from
each subject. Cells were maintained as defined in DMEM, McCoy’s,
RPMI, or IMEM (ATCC) supplemented with 100U of penicillin,
100mgml
 1 streptomycin, 300mgo fL-glutamine, and 10–20% heat
inactivated fetal bovine serum (FBS; ATCC). Cells were grown at
371C in a humidified atmosphere of 95% air, 5% CO2 until 60%
confluent and supernatants were removed. New medium was given
and cells were grown to 90% confluent, after which supernatants
were collected, centrifuged for 10min at 2500r.p.m., and stored at
 201C until use.
Expression plasmid and generation of stable cell lines
The detailed procedure for cloning and propagation has been
described previously (Ogawa et al, 2002; Shi et al, 2003). In brief,
recombinant retroviruses expressing a bicistronic messenger RNA
containing open-reading frames of Flag-HA (haemagglutinin)-
tagged human survivin or human T34A survivin and interleukin-2
receptor (IL-2R)-a were constructed and transduced into HeLa
cells. The infected HeLa cells were sorted by anti-IL-2R mono-
clonal antibody (mAb) conjugated with magnetic beads, and the
resulting Flag-HA-survivin or Flag-HA-T34A survivin stable cell
lines propagated as suspension cultures. The expression level
of both the wild-type (WT) and mutant (T34A) survivin was
evaluated by western analysis and immunohistochemistry with
anti-Flag and HA antibodies (Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA).
Survivin depletion
Conditioned medium (CM) from stable survivin-expressing HeLa
cells contains survivin that has a Flag-HA tag as well as normal
endogenous survivin. To deplete the medium of survivin, we added
anti-Flag beads (20mlml
 1) to the medium and rotated overnight
at 41C. The medium was centrifuged at 2000r.p.m. for 5min to
pellet the beads. The supernatant was collected and 100ml set aside
for analysis by ELISA. The pelleted beads were collected and put in
at  201C. The remaining medium was treated with anti-HA beads
(20mlml
 1) in a similar manner to remove the remaining tagged
survivin. To deplete the endogenous survivin, we added anti-
survivin polyclonal antibodies (10mlml
 1) and anti-rabbit beads
(20mlml
 1) to the medium and rotated overnight at 41C. The
100ml aliquots at each stage were used in an ELISA to confirm the
depletion. The beads collected at each step were incubated in 40ml
sample loading buffer at 1001C for 4min, then centrifuged at
2000r.p.m. for 5min. A western blot of the supernatant was used
to further confirm depletion.
Quantitation of survivin from CM (cell culture
supernatants)
Conditioned medium was collected from 90% confluent cell
cultures with cell viability assessed by Trypan blue exclusion
(Sigma-Aldrich, St Louis, MO, USA). One-half of the medium was
concentrated 4  using a speed-vac (Savant OligoPrep 120) after
which unconcentrated and concentrated samples were assayed for
the presence of survivin using the Quantikine Human Survivin
immunoassay kit (R&D Systems Inc., Minneapolis, MN, USA),
according to the manufacturer’s instructions. To quantify repre-
sentative survivin protein from cultures experiencing cell death, we
grew HeLa cells to 90% confluence as previously described after
which 0.1, 1.0, and 10% of these cells were lysed and their protein
used to ‘spike’ control medium for ELISA.
Immunofluorescence localisation of protein
Cells were plated in six-well plates on 22 22mm coverslips and
cultured with 2ml of control or CM (Surv-WT-CM, Surv-T34A-
CM). Wells were washed with PBS and fixed in 4% paraformalde-
hyde for 30min at room temperature. Cells were permeabilised
with 0.5% NP-40 in PBS for 15min, blocked with 5% FBS in 0.01%
NP-40/PBS for 30min, incubated for 1h with 1:500 dilution of
anti-Flag/HA mAbs (Sigma-Aldrich). Cells were incubated with
Alexa Fluor-555-conjugated rabbit anti-mouse IgG secondary
antibody (Invitrogen/Molecular Probes, Eugene, OR, USA),
mounted with Vectashield mounting media containing DAPI
(Vector Laboratories, Burlingame, CA, USA) and observed
( 1000) under an Olympus BX50 fluorescent microscope
(Olympus America Inc., Center Valley, PA, USA).
Image acquisition using laser-scanning confocal
microscopy
Sampled sections were imaged and analysed with an Olympus FV
1000 laser-scanning confocal imaging system mounted onto an
Olympus IX81 microscope (Olympus America Inc.). Microscopic
data were acquired with a 60  oil immersion objective lens. In
each section, confocal stack images from representative fields of
view per section were captured. The distance between each focal
plane was 1mm.
Protein expression and purification
Recombinant WT or mutated (T34A) proteins were expressed
as glutathione-S-transferase (GST) fusion proteins in the
Escherichia coli BL21-CodonPlus-RIL (Stratagene, La Jolla, CA,
USA) strain with induction in 0.2mM isopropyl-b-D-thiogalacto-
pyranoside (IPTG) for 5h at 301C. BIRC5 (survivin) was purchased
from Abnova (Walnut, CA, USA). The cells were harvested by
centrifugation at 6000g for 20min, suspended in 50mM Tris
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s(pH 7.4), 150mM NaCl, 5mM MgCl2, and 1mM dithiothreitol, and
lysed by sonication. After centrifugation at 15000g for 30min, we
mixed the soluble fractions with glutathione-agarose beads
(Sigma-Aldrich) and incubated for 1h at 41C. After centrifugation
at 1000g for 1min, we washed beads containing proteins three
times in 50mM Tris (pH 7.4), 500mM NaCl, 5mM MgCl2, and 1mM
dithiothreitol and further purified by chromatography over Econo-
Column (Bio-Rad, Hercules, CA, USA) after overnight thrombin
(Sigma-Aldrich) treatment to release the GST frame. The protein
concentrations were measured using a protein assay reagent
(Pierce, Rockford, IL, USA) with BSA as standard. Recombinant
transferrin protein was purchased from Sigma-Aldrich. The
expression vector PRSET-CTB contained a gene encoding the
entire cholera toxin B subunit (CTB) protein (11.6kDa), driven by
the T7 bacteriophage promoter region and containing an
oligonucleotide encoding 6 histidines immediately upstream of
the CTB gene for nickel column isolation of the recombinant
protein was built as described (Carter et al, 2006). Briefly, CTB
protein synthesis was stimulated by addition of 90mg IPTG to the
bacterial culture for 6h at 371C. Cells were harvested by
centrifugation with the pellet resuspended in 10mM HEPES buffer
(pH 7.5), containing 100mM imidazole. The cells were disrupted by
sonication at 3 10s bursts at 10W, with a Sonic 60 Dismem-
brator. Cholera toxin B subunit protein was isolated from the
homogenate by a Maxwell Model 16 robotic protein purification
system (Promega Inc., Madison, WI, USA), according to the
protein isolation protocol provided by the manufacturer. Purity
of the isolated CTB protein was determined by electrophoretic
mobility measurement in a 12% polyacrylamide gel. Imidazole was
removed from the protein mixture by dialysis of the preparation
against 10mM HEPES buffer (pH 7.5), for 4h at 41C.
IR-Dye labelling of recombinant proteins and in-cell
western blotting
IR-Dye labelling was performed according to the manufacturer’s
instructions (LI-COR Biosciences, Lincoln, NE, USA). Briefly,
100mg of transferrin, CTB, and 10mg of BIRC5 was labelled at 201C
for 2h. Labelled protein was column purified as described by the
manufacturer. HeLa cells (5 10
3 per well) were plated in 96-well
plates. After overnight culture, we added labelled BIRC5,
transferrin, and CTB proteins at doses of 1mg, 0.01mg, and
0.001mg in duplicate wells. After overnight culture, we washed cells
vigorously 3–4 times with PBS to remove all remaining unattached
recombinant protein. Cells were fixed with 4% paraformaldehyde
and an in-cell western blot was performed using survivin
polyclonal antibody (Novus, Littleton, CO, USA) according to the
manufacturer’s instructions. The 96-well plate was then scanned
immediately in both 700 and 800nm channels. Relative fluorescent
intensity was determined using our Odyssey Infrared Imaging
system and software.
Colony formation assay
The cells were plated in 10cm dishes at a density of 100 000 cells
per well, incubated at 371C overnight, and then were treated with
the indicated control, Surv-WT-CM, and Surv-T34A-CM for up to
48h. The cells were fixed with methanol and stained with crystal
violet.
Cell-cycle synchronisation
HeLa-S cells were G1-arrested for 16h using mimosine as
previously described (Li et al, 1999). Cells were then released
and treated with either Surv-WT-CM or control medium and then
harvested after 0, 3, 6, 9, and 12h. Cells were analysed for DNA
content by propidium iodide staining and flow cytometry (Becton
Dickinson, San Jose, CA, USA).
Apoptosis and cell-cycle analysis
Subconfluent cultures of the various cell lines were incubated with
vehicle (DMSO), taxol (4mM; Sigma-Aldrich), 5-flurouracil (5-FU,
200nM; Sigma-Aldrich), adriamycin (Ad, 100nM, Sigma-Aldrich),
cisplatin (CDPD, 2mM; Sigma-Aldrich) or exposed to ultraviolet B
(UVB) irradiation at 50Jm
 2 with or without the presence of
WT-CM, T34A-CM, or control for 24 and 48h at 371C. Cells were
harvested, prepared, and analysed for DNA content as described
previously (Li et al, 1999). DNA content was analysed using a
Becton Dickinson FACScan flow cytometer (Becton Dickinson).
The distribution of cells in the different phases of the cell cycle was
analysed from DNA histograms using BD CellQuest software
(Becton Dickinson).
AlamarBlue (AB) assay for cell proliferation
Initial experiments were carried out to follow per cent AB (%AB)
reduction over time. The aim was to determine the optimal seeding
density and culture period. HeLa cells, trypsinised from subcon-
fluent cultures as described earlier, were suspended in culture
medium containing 1% FBS, T34A-CM, and WT-CM and then
seeded into duplicate wells of a 96-well plate (200ml well) at
concentrations of 1.5 10
4–1 10
6 cells per ml at standard
culture conditions of 5% CO2 in air at 371C. After an initial 4h
period to allow for cell attachment, we added AB (BioSource,
Camarillo, CA, USA) directly into culture medium at a final
concentration of 10% and the plate was returned to the incubator.
Optical density of the plate was measured at 540 and 630nm with a
standard spectrophotometer at 1, 3, 6, 12, 24, 48, and 72h after
adding AB. Because the culture medium was not changed during
this period, the calculated %AB reduction is a cumulative value. As
a negative control, AB was added to medium without cells.
Caspase activity assay
Caspase activity was quantitated using the ApoAlert Caspase Assay
Plates (Clontech, Mountain View, CA, USA). Fluorogenic sub-
strates specific for caspase-3, caspase-8, caspase-9, and caspase-2
were immobilised in the wells of a 96-well plate. Fluorescence was
detected using a standard fluorescence plate reader in the presence
or absence of the specific caspase inhibitor.
Western blot analysis
Cells were solubilised, proteins (20–40mg) separated using 12% Bis-
Tris polyacrylamide gels, proteins transferred onto polyvinylidene
difluoride membranes (Millipore, Temecula, CA, USA) and probed
using the following antibodies: mouse monoclonal anti-Flag and
anti-HA (Sigma-Aldrich), rabbit polyclonal anti-survivin (Novus),
rabbit polyclonal antibodies to caspase-7, caspase-9, PARP and
GAPDH (Cell Signaling Technologies, Beverly, MA, USA), mouse
mAbs to b-actin (Abcam, Cambridge, MA, USA), and mouse mAb
to caspase-2 (Cell Signaling Technologies). Secondary antibodies
(IR-Dye-conjugated) were goat anti-rabbit and goat anti-mouse
immunoglobulin (LI-COR Biosciences). Immunoreactive bands
were detected using the Odyssey imaging system (LI-COR
Biosciences) and quantified using ImageQuant software (Amersham
Biosciences, Piscataway, NJ, USA). Protein quantifications presented
in this report were normalised with respect to b-actin or GAPDH.
Mitochondrial permeability detection
Mitochondrial depolarisation is detected by a unique fluorescent
cationic dye 5,50,6,60-tetrachloro-1,10,3,30-tetraethyl-benzamidazo-
locarbocyanin iodide, also known as JC-1 (Invitrogen/Molecular
Probes). Cells were collected and washed with PBS and prepared
for the analysis according to the manufacturer’s instructions.
Survivin in the tumour microenvironment
S Khan et al
1075
British Journal of Cancer (2009) 100(7), 1073–1086 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sCollagen cell invasion assay
Cellular invasion was studied using the QCM 96-well Fluorometric
Collagen-based Cell Invasion Assay from Chemicon International
(Millipore) according to the manufacturer’s instructions. Briefly,
single-cell suspensions were obtained by trypsinisation of mono-
layer cultures of HeLa cells. Cell counts and viability were
performed using Trypan blue staining after overnight serum
starvation. Cells (25000 cells per well) were plated on 8mm pore
size collagen-coated inserts in 96-well plates. Cells were grown for
24h with control media, Surv-WT-CM, Surv-T34A-CM, medium
that was depleted of survivin introduced into the lower chamber or
medium taken from cells treated with cytochalasin D, a known
inhibitor of exocytosis that works by specifically disrupting
microfilaments. Survivin was depleted using one round of anti-
Flag antibody, one round of anti-HA antibody, and either 1
(depleted 1 ) or 3 (depleted 3 ) rounds of anti-survivin
antibody. A control, termed blank, was performed using only cell
detachment buffer, lysis buffer, and CyQuant dye without cells.
Invasive cells, migrating through the polymerised collagen layer,
were dissociated using cell detachment buffer as described by the
manufacturer and lysed. Fluorescence emission (CyQuant GR dye)
was assessed by a fluorescent plate reader (Molecular Dynamics,
Sunnyvale, CA, USA).
Statistical analysis
Statistical analysis was performed using a two-way analysis of
variance with the aid of JMP statistical software (Cary, NC, USA).
A paired t-test was used for group analysis. Caspase-2, caspase-7,
and caspase-9 densitometric analysis was conducted using our
AlphaImager EC (Alpha Innotech, San Leandro, CA, USA). Density
of individual bands was divided by GAPDH as the internal control
with each timed sample then divided by the particular time period
control. As 6h staurosporine did not have a 6h control, these were
also controlled against the 24h control samples.
RESULTS
Stable expression of wild-type and mutant T34A survivin
leads to survivin secretion
We and others (Bokarewa et al, 2005; Mera et al, 2008) recently
found and reported a form of survivin that is found in the
extracellular space. Using a commercially available survivin ELISA,
we were able to quantitate picogram amounts of survivin from CM
taken from tumour cell lines representative of the most common
cancer types, including pancreatic, breast, prostate, cervical,
sarcoma, and acute monocytic leukaemia (Table 1). To determine
whether this extracellular form of survivin was merely released as a
result of an excretory process, the result of cellular necrosis, or
whether its function was secretory and would be important in the
context of the tumour microenvironment, that is absorbed into
cells, we needed to construct a form of survivin different from the
endogenous form. We therefore generated stable HeLa cells
expressing human survivin (Surv-WT) tagged with both the Flag
and HA epitopes at their N terminus. Immunohistochemistry
(Supplementary Figure 1A) as well as western blotting (Supple-
mentary Figure 1C) using antibodies to either HA or Flag revealed
the survivin fusion protein.
The Surv-T34A mutant has shown promise in initiating the
mitochondrial apoptotic pathway (Mesri et al, 2001) and if also
detected extracellularly could provide a form of survivin suitable
for therapeutic manipulation. We therefore generated stable HeLa
cells expressing the non-phosphorylatable Surv-T34A mutant.
Immunohistochemistry (Supplementary Figure 1B) and western
blotting (Supplementary Figure 1C) revealed the HA-Flag-survivin
fusion protein. The generation of this cell line took many attempts,
and many months, as the Surv-T34A mutant was very toxic to the
HeLa cells. Further analysis of allowing mutations has not yet
taken place.
Conditioned medium taken from these stable Surv-WT or
Surv-T34A HeLa cells showed picogram amounts of survivin by
ELISA (Table 1). Interestingly, it was quite apparent that
Table 1 Quantitative analysis of survivin in conditioned medium of cancer cell lines by ELISA
Cell type Cell lines pgml
 1 s.e.m. Concentrated (pgml
 1) s.e.m.
Cervical cancer HeLa ND — 330.4 11.4
HeLa-S 94.0 42.1 746.1 1.4
HeLa-S-Surv-WT 619.0 24.3 1158.3 32.1
HeLa-S-Surv-T34A 35.2 0.01 81.9 0.01
HeLa-S-survivin
Antibody depletion
ND — ND —
Pancreatic cancer Capan1 246.9 13.6 1204.7 14.3
Capan2 ND — 26.1 8.6
Panc1 20.4 42.9 174.7 47.1
Prostate cancer PC3 73.3 32.9 888.3 5.0
Du-145 136.9 37.4 771.9 24.0
RWPE-2 29.0 16.0 337.6 7.0
Osteosarcoma U2OS ND — 210.4 14.3
SaOS2 405.4 50.0 858.3 50.7
Breast cancer MCF-7 63.0 2.0 175.4 1.7
HCC TN ND — 19.0 1.4
Acute monocytic leukaemia MOLM-14 ND — 273.3 23.3
MV4-11 ND — 347.6 15.9
Human bone marrow stroma HBMS (normal) ND — ND —
Prostate epithelial cells PrECs (normal) ND — ND —
Prostate stromal cells PrSCs (normal) ND — ND —
Peripheral blood mononuclear cells PBMCs (normal) ND — ND —
Media control Media control ND — ND —
Spiked media control 0.1% lysed cells ND — 3.2 0.7
1.0% lysed cells 77.6 1.1 121.9 2.0
10% lysed cells 259.7 8.3 596.1 37.0
ND¼none detected.
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saccumulation of the T34A mutant survivin and that from the parent
HeLa-S cells was limited in comparison to that which accumulated
in the medium from the Surv-WT cells (Table 1). To evaluate this
disparity, we evaluated survivin protein concentration, determined
using ELISA, on a per cell basis. Dividing the measured amount of
protein by the number of cells that were present provides evidence
that the Surv-WT cells truly do release more protein into the CM
than does the control cells or the Surv-T34A-producing cells
(Figure 1A). AB staining was next used to determine if this
phenomenon was the result of cellular division. As recorded in
Figure 1B, AB reduction in the Surv-WT HeLa-S cells represented a
state of enhanced cellular growth when compared to the controls or
the Surv-T34A cells. Surv-T34A HeLa-S cell proliferation is
significantly reduced when compared to the Surv-WT and control
HeLa-S cells. Also, there was no significant difference in the level of
cell proliferation recorded in the Surv-T34A-expressing cells when
compared to medium where no cells were being grown (Figure 1B,
blank), indicating that Surv-T34A may reduce the level of released
survivin as a result of its stifling cell growth.
We next evaluated the functional importance of this extra-
cellular survivin protein. HeLa cells were incubated for 24h in
CM taken from control, Surv-WT, or Surv-T34A stable cells.
Immunohistochemical staining (Figure 2A) and western blotting
(Figure 2B), using antibodies to HA, showed that the survivin
fusion proteins are readily taken up. A retarded band of
approximately 18kDa appeared in the HeLa-S lysates of cells
incubated in WT- and T34A-CM representing the Flag-HA-
survivin fusion protein (Figure 2B), which was not observed in
control conditioned medium grown HeLa cells. Interestingly, the
cells that were incubated in Surv-T34A-CM took on a shrunken
appearance and were fewer in number compared to the control
medium-incubated cells (Figure 2A) whereas the Surv-WT, CM-
incubated cells appeared to be healthier and in greater numbers.
Phase-contrast microscopy allowed enhanced visualisation of this
shrunken phenotype and the initiation of apoptotic bodies in these
T34A-CM-treated cells. To ensure that the ability of cells to uptake
survivin from the CM was a general occurrence and not specific for
the HeLa cells, we also incubated Capan1, Capan2, MCF-7, Panc1,
PC3, SaOS2, U2OS, HCC, and HBMS cells in HA-Flag-survivin-
containing CM. All cancer cells were able to take up the survivin
from the medium whereas the normal HBMS cells did not
(Figure 3A). Western blots (Figure 3B) from these cells confirmed
the uptake results as every cell type except HBMS, when incubated
in Surv-WT-CM, expressed 18kDa band representing the Flag-HA-
survivin fusion protein. Previous work performed on neutrophils
showed survivin not entering the cells but binding to the surface
(Mera et al, 2008). It was therefore necessary to perform confocal
microscopy to ensure survivin’s relocalisation within the cells.
Taking photographs at 1mm increments throughout the cell
(shown schematically in Figure 4K) indicated that in these HeLa
cells, survivin was not only inside the cells but also relocalised
within the cytoplasm and to the nucleus (Figure 4).
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Figure 1 Comparison of extracellular survivin protein concentrations and cellular metabolism of the cervical carcinoma HeLa cells that were stable
transfectants of the survivin-WT (Surv-WT) or mutant survivin T34A (Surv-T34A). (A) ELISA-defined survivin concentrations were measured in medium
taken from the different stable HeLa cells lines as described in Materials and methods section. For each cell line, the survivin protein concentration was
divided by the number of cells defined by Trypan blue exclusion at the time of medium collection. (B) Alamar Blue fluorimetry was conducted in the same
three cell lines to determine if the stable expression of survivin or its mutant would affect the cell growth and metabolism. Measurements were also
conducted in medium containing no cells (blank), which would represent no growth or metabolism. Data are the mean±s.e. of three independent
experiments (*Po0.001) as compared to the control.
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sRelationship between survivin absorption,
Surv-T34A-induced apoptosis, and Surv-WT-induced
cell-cycle progression
Consistent with the data presented in Figure 2A, HeLa cells grown
in CM taken from stable Surv-T34A cells experienced enhanced
numbers of hypodiploid cells, that is, sub-G1 DNA content or
apoptotic cells (Figure 5A, inset) by DNA content analysis and
flow cytometry. Furthermore, Trypan blue exclusion and colony
formation assay evaluation of these same cells showed a time-
dependent, marked reduction in live cell numbers and live cell
colonies in the Surv-T34A-CM-grown HeLa cells compared with
cells grown in control medium or the CM from the Surv-WT cells
(Figures 5A and B and Supplementary Figure 2). This cell number
reduced even further after 48h as shown by the live cell colonies in
the Surv-T34A-CM-grown HeLa cells, a finding that is consistent
with what has been recorded by our own group and others (Mesri
et al, 2001; O’Connor et al, 2002; Wall et al, 2003; Ogura et al,2 0 0 8 )
that the dominant-negative survivin mutant T34A induces as
caspase-dependent apoptosis. In contrast, Trypan blue exclusion
and colony formation assay evaluation of Surv-WT-CM-grown cells
showed a time-dependent, marked increase in live cell numbers
(four times) and live cell colonies (approximately two times), in
comparison with cells grown in control medium or the CM from the
Surv-T34A cells (Figures 5A and B and Supplementary Figure 2).
To further evaluate the cell-cycle progression effects observed in
the Surv-WT-CM-grown cells, we mimosine synchronised HeLa
cells for 16h, which effectively arrested cells in the G0/G1 phase of
the cell cycle. Mimosine was then removed and the cells were
incubated in the absence or presence of Surv-WT-CM. Cells were
then harvested at 0, 3, 6, 9, and 12h time points following CM
addition and cells were analysed by DNA content analysis and flow
cytometry. In comparison with cells grown in control medium,
Surv-WT-CM-grown cells had a 10–12% increase in S-phase growth
in cells harvested after 6h and a 10% increase in the number of cells
in G2/M by 12h (Figure 5C). These findings are consistent with
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Figure 2 HeLa cells incubated in Surv-WT- or Surv-T34A-conditioned medium take up the Flag-HA-survivin fusion protein. (A) HeLa cells were cultured
with control-, Surv-WT-, or Surv-T34A-conditioned medium for 24h. Cells were fixed and stained with antibodies to HA, magnification  1000. Insets are
western blots taken from cell lysates of these cells probed with antibodies to HA. Phase-contrast panels show the T34A-associated shrunken phenotype and
early apoptotic bodies in comparison with the control or WT-treated cells. (B) Western blot analysis using antibodies to both survivin and Flag shows the
retarded B18kDa band of the Flag-HA-survivin fusion protein. Control lysates only show the presence of the 16.5kDa endogenous survivin. Molecular
weight markers in kilodaltons (kDa) are shown on the left.
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sthose published indicating that survivin displays both anti-
apoptosis and promotion of mitosis in cancer cells (Li et al, 1998;
O’Connor et al, 2000; Chao et al, 2007). We are further encouraged
as our CM containing fusion proteins may prove useful for the
future study of survivin trafficking and T34A therapy in vivo.
Recombinant survivin protein lacks the function of
survivin-containing CM
Recombinant Surv-WT and Surv-T34A proteins were incapable of
affecting cell growth or apoptosis in our hands (Supplementary
Figure 3). It is uncertain whether bacterial-derived survivin
proteins are folded or modified properly for recognition by
cellular mechanisms of uptake. To test this hypothesis further, we
evaluated recombinant survivin (BIRC5), transferrin, and CTB
proteins for cellular uptake using in-cell western assay methods
(Egorina et al, 2005). HeLa cells were incubated with increasing
concentrations of labelled recombinant protein, and the amount of
protein endocytosed after a 12h incubation was measured as
shown in Figure 6. The amount of transferrin and CTB proteins
endocytosed increased in a dose-dependent manner. However,
survivin recombinant protein (BIRC5) at the same concentrations
was not endocytosed (Figure 6). Transferrin (Sandvig and van
Deurs, 1990) and CTB (Gizurarson et al, 1992; Frey et al, 1996;
B
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Figure 3 Cancer cells but not normal cells incubated in Surv-WT-conditioned medium take up the Flag-HA-survivin fusion protein. (A) HeLa, Capan1,
Capan2, MCF-7, Panc1, PC3, SaOS2, U2OS, HCC, and HBMS cells were cultured with control- or Surv-WT-conditioned medium for 24h. Cells were fixed
and stained with antibodies to HA, magnification  1000. (B) Western blot analysis using antibodies to survivin shows the retarded B18kDa band of the
Flag-HA-survivin fusion protein only in those lysates from the cells grown in conditioned medium. A third band, labelled *, often appears after probing with
the antibodies survivin whose identity is yet unknown to us. Molecular weight markers in kilodaltons (kDa) are shown on the left.
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sHansen et al, 2005) recombinant proteins were previously
described as substrates for endocytic uptake and were used as
positive controls.
Characterisation of tumour cell apoptosis induced by
Surv-T34A in vitro
We have shown in Figures 2A and 5A that incubating HeLa cells
with Surv-T34A-CM resulted in apoptosis. Cytofluorometric
quantification results showed that in comparison with control
media or Surv-WT-CM treatment, Surv-T34A treatments induced
robust results within 24 to 48h. Previous studies performed, using
an adenovirus-encoding T34A mutant, resulted in apoptosis that
was associated with the mitochondrial release of cytochrome c,
cleavage of caspase-9, and the processing of caspase-3 (Mesri et al,
2001). Further analysis of Surv-T34A-CM-induced apoptosis, using
a commercially available caspase activity assay, revealed that
Surv-T34A induced cleavage of caspase-9 and caspase-2 without
cleaving the substrates specific for caspase-3 or caspase-8
(Figure 7A). The antibiotic and protein kinase inhibitor, stauro-
sporine, was used as a positive control for caspase-3 activity. Surv-
WT-CM had no effect on the caspase activity under evaluation.
In addition, western blotting provided biochemical data that
supported studies recorded above for caspase-2, caspase-3, and
caspase-9. Using antibodies that were specific for the full-length,
non-cleaved forms of caspase-2, caspase-7, and caspase-9 and the
cleaved form of caspase-3 protein and staurosporine again as a
positive control, we found that Surv-T34A induced the parallel
time-dependent reduction in caspase-2, caspase-7, caspase-9, and
cleavage of the DNA repair protein PARP (Figure 7B). In all cases
the pan-caspase inhibitor Z-VAD-FMK was able to inhibit the
activity of Surv-T34A. In contrast, Surv-WT again had no obser-
vable effects on caspase cleavage when cells were treated with it
alone for up to 48h. Caspase-3 was robustly cleaved after 6h
of staurosporine treatment. However, this cleavage product was
absent after 24h indicating a complete cleavage and degradation of
caspase-3. Concomitant with this cleavage was the significant level
of PARP cleavage recorded at this 24h time point.
Loss of mitochondrial membrane potential after treatment
with Surv-T34A CM
Mitochondrial membrane potential (Dcm), a phenomenon readily
measured using the mitochondrial dye JC-1 and fluorescence-
activated cell sorting analysis (Salvioli et al, 1997), was evaluated
for the possibility that Surv-T34A was stimulating apoptosis by
inducing depolarisation within the mitochondria. Under normal
circumstances, JC-1 accumulates in the inner mitochondrial
membrane in which it oligomerises and fluoresces red. A reduction
in Dcm results in diffusion of the dye from the mitochondria and a
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Figure 4 Confocal microscopy indicates that survivin protein is taken up by cancer cells and is not merely binding to the cell surface. Cells were fixed and
stained with antibodies to HA, with pictures taken on a z-scale of 1mm, magnification  1000. (A–J) are z-scale pictures taken at 1mm intervals as
represented in (K).
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ssubsequent reduction in the mean red fluorescent intensity. As
expected, control HeLa cells showed a high mean red fluorescence
(set to B96%) after staining with JC-1 (Figure 7C). After treatment
with staurosporine, we found that the mean red fluorescence of the
mitochondria dropped rapidly within 6h, indicating that the Dcm
had collapsed (Figure 7C). HeLa cells treated with Surv-T34A, but
not Surv-WT, showed a time-dependent reduction in the mean red
fluorescence intensity. However, in repeated experiments this was
always slower than that seen for staurosporine (Figure 7C). This
may indicate that mitochondrial depolarisation due to Surv-T34A
is a secondary event and not the primary effect of Surv-T34A-
induced killing or that mitochondrial depolarisation is one of
many factors involved in Surv-T34A-induced killing.
Effect of Surv-T34A and Surv-WT and UV radiation on
tumour cell apoptosis
Incubation of HeLa cells with UV radiation resulted in enhanced
numbers of hypodiploid cells, which are sub-G1 DNA content or
apoptotic cells (Figure 8A) by DNA content analysis and flow
cytometry. In comparison to control cells that were set at B5%,
UV radiation treatment resulted in 35% of the cells exhibiting a
sub-G1 DNA content. However, cells grown for 24h in Surv-WT-
CM before UV treatment were fully protected from the effects of
the UV energy. In turn, Surv-T34A enhanced the killing effects of
the UV and resulted in 75% of the cells exhibiting a sub-G1 content
(Figure 8A).
Effect of Surv-T34A and Surv-WT and chemotherapeutic
drugs on tumour cell apoptosis
To establish that the effects recorded in HeLa cells were not
specific for this cell line alone or for UV radiation, we selected
human pancreatic adenocarcinoma (Capan1 and Capan2) cell lines
to study drug sensitivity and responsiveness in the presence or
absence of Surv-WT- and Surv-T34A-CM. Effects of taxol, 5-FU,
Ad, and CDPD were studied. Capan1 cells exhibited an enhanced
susceptibility to taxol, 5-FU, Ad, CDPD-induced cell death after the
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Figure 5 Surv-T34A-conditioned medium induces tumour cell apoptosis whereas Surv-WT-conditioned medium promotes cell growth. (A) Cervical
carcinoma HeLa cells were grown in the presence of either Surv-T34A- or Surv-WT-conditioned medium for 24 and 48h, harvested and analysed for DNA
content by propidium iodide staining and flow cytometry (inset) or Trypan blue exclusion. Percentages of apoptotic cells with hypodiploid (sub-G1) DNA
content are indicated per each condition tested. Data are representative of one of two or three independent experiments with comparable results.
(B) HeLa cells, grown as described, were fixed with methanol and stained with crystal violet allowing visualisation of the enhanced cellular proliferative
effects of Surv-WT or the killing/growth-repressive effects of Surv-T34A. The data presented are the mean colony formation efficiency±s.d. in three
experiments. (C) Mimosine-synchronised HeLa cells were harvested at the indicated increasing time intervals after release and analysed for DNA content by
propidium iodide staining and flow cytometry. A full colour version of this figure is available at the British Journal of Cancer online.
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saddition of Surv-T34A-CM, whereas Surv-WT-CM-incubated cells
were protected from taxol, 5-FU, and CDPD-induced cytotoxicity
(Figure 8B). Only a modest protection was recorded against Ad.
Interestingly, Surv-WT-CM treatment protected Capan2 cells from
the cytotoxic effects of 5-FU and again only a modest protection
was recorded against taxol, Ad, and CDPD. Treatment of Capan2
cells with Surv-T34A-CM was as effective as taxol, more effective
than CDPD and 5-FU and less effective as Ad alone. Surv-T34A
when combined with taxol showed an additional cytotoxicity that
may be quantitatively additive at best. When combined with
CDPD, Surv-T34A did not provide further enhancement to the
killing effects over that of Surv-T34A alone, which was substantial,
and when paired with 5-FU or Ad, the individual cytotoxic effects
of Surv-T34A were reduced (Figure 8C).
Survivin containing CM induces cancer cell invasion
in vitro
To determine the function of secreted survivin in regulating cancer
cell invasion through collagen, we plated HeLa cells on collagen-
coated inserts in the presence of control, Surv-WT-, or Surv-T34A-
CM. Cells were grown for 24h, dissociated, lysed, and then
evaluated for invasion by measuring the fluorescence emission
(CyQuant GR dye). HeLa cells exhibited an average fourfold
increase in cell invasion when grown with Surv-WT-CM in the
lower chamber as compared to control medium (Figure 9). Surv-
T34A-CM invasion levels were little changed from that of the
control as were those cells that were treated with medium that had
been depleted of survivin.
DISCUSSION
The growth and spread of cancer depends as much on the host
response to the tumour as on the biological characteristics of the
tumour itself. The IAP survivin has been shown aberrantly
expressed in cancer but undetectable in normal differentiated
adult tissue. It has been implicated in both control of apoptosis
(Ambrosini et al, 1997; Adida et al, 1998) and regulation of cell
division (Deveraux and Reed, 1999; Li et al, 1999; Gianani et al,
2001). Indeed, survivin expression has been shown to be cell-cycle
regulated with its highest expression in G2/M phase, and it has
been shown that much of its function comes from its subcellular
localisation with residences in the cytosol, nucleus, and mitochon-
dria (Li et al, 1999; Li, 2003). Recent reports on patients with
rheumatoid arthritis have described a new survivin localisation
and the possibility that it may also function in the extracellular
space (Bokarewa et al, 2005; Mera et al, 2008). Moreover, in these
patients, extracellular survivin was directly linked to an erosive
course of joint disease and its origin was prescribed to peripheral
blood leukocytes where its expression is constitutive. Furthermore,
survivin was shown to bind extracellularly to neutrophils inducing
the p38-MAPK-dependent expression of a- and b-integrins
(Mera et al, 2008). Taken together, the finding of a new and
physiologically functional pool of survivin provides new insight
into the function of IAPs as well as other relevant tumour-
associated proteins in the tumour microenvironment.
In this study we have shown that an extracellular form of
survivin is detectable in CM taken from cancer cells. We also
demonstrate that unlike survivin from the rheumatoid arthritis
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Figure 6 Recombinant survivin protein is unable to cross the HeLa cell membrane. (A) Detection of cellular recombinant proteins. These images show a
portion of a 96-well plate. The right panel is a composite image showing the fluorescence in both the 700- and 800-nm detection channels. Duplicate rows
of microplate wells loaded with 0.001, 0.01, or 1.0mg of protein are shown. The middle panel shows detection of endogenous survivin protein, which was
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fluorescence. Recombinant protein signal has been normalised using the endogenous survivin protein signal from each well to correct for well-to-well
variation in cell number. Recombinant protein (rProtein).
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sstudy, survivin from cancer cells is readily taken up by cancer cells
rather than binding only to their surface (Mera et al, 2008). Finally,
upon incubation in medium containing this extracellular pool of
survivin, cancer cells responded physiologically, becoming more
resistant to therapy, proliferating more rapidly, and having an
increased metastatic potential. These findings lead us to believe
that extracellular survivin may modulate, in vivo, the tumour
microenvironment for the purpose of tumour evolution and these
findings in part may be responsible for the observations that
patients with a high expression of survivin protein display
advanced disease, high-grade disease, abbreviated survival, resis-
tance to therapy, and accelerated tumour recurrences (Andersen
et al, 2007).
We have also shown that stable cells expressing the previously
described (Mesri et al, 2001; O’Connor et al, 2002) pro-apoptotic
survivin mutant Thr
34-Ala (Surv-T34A) release a form of
survivin that is able to disrupt the cell cycle and cause a
caspase-dependent, mitochondrial depolarisation-associated apop-
tosis. When combined with UV radiation or with the chemo-
therapeutic agents taxol, Ad, CDPD, or 5-FU, Surv-T34As pro-
apoptotic ability was amplified. It was not surprising that these
modalities were differentially enhanced or inhibited by Surv-T34A
or Surv-WT because they have varied mechanisms of action. Surv-
T34A was found to be as effective in enhancing therapy-induced
cell killing as Surv-WT was in protecting against therapy-induced
cell killing. These differential effects seemed not to follow the
p53 status of the cell lines tested as Surv-WT was as effective
at protecting those cells lacking the tumour suppressor and
transcription factor as it was for those cells positive for p53. It
has been shown that survivin gene transcription is repressed by
WT p53 (Li, 2003) but little is known of p53’s ability to modify the
protein’s function. A more careful evaluation of this finding is
required.
The precise mechanism by which this survivin mutant causes
apoptosis is still incompletely understood. The mutations that
allowed for the generation of stable cells as well as their ability to
induce apoptosis through the caspase-2- and caspase-9-dependent
pathways are currently being evaluated in our laboratory.
Importantly, a quantifiable highly stable extracellular form of
survivin has been identified. This novel T34A survivin molecule is
readily taken up by cancer cells after which characteristics of
apoptotic cell death are measurable. Further, it potentiates the
killing effects of other cancer therapeutics. It is our belief that this
extracellular Surv-T34A molecule has significant potential as a
novel therapeutic or as part of a novel therapeutic and possible
immunotherapy regimen.
Tumour invasion and metastasis are very complex processes
that are yet very poorly understood but account for 90% of all
human cancer deaths (Sporn, 1996; Hanahan and Weinberg, 2000).
The mechanism involves coupling and uncoupling of cells to
their microenvironment, activation of extracellular proteases, and
modulation in tethering proteins such as cadherins, b-catenin, and
integrins (Hanahan and Weinberg, 2000). As survivin has already
been shown to modulate the integrin proteins CD49d, CD11b, and
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Figure 7 Conditioned medium containing survivin affects the intrinsic
apoptotic pathway. (A) Caspase catalytic activity. Aliquots of HeLa cells
grown in the presence of either Surv-T34A- or Surv-WT-conditioned
medium were assayed for caspase-3/7, caspase-8, caspase-9, and caspase-2
activity by Ac-DEVD-AMC, IETD-AMC, LEHD-AMC, and VDVAD-AMC
hydrolysis, respectively, in the presence or absence of the caspase-3
inhibitor, DEVD-CHO; the caspase-8 inhibitor, IETD-fmk; the caspase-9
inhibitor, LEHD-fmk; or the caspase-2 inhibitor, VDVAD-fmk. Inhibitor
(INH), staurosporine (STR). Data are the mean±s.e. of two independent
experiments. (B) Caspase activation. Detergent-solubilised extracts of
HeLa cells grown in Surv-WT- or Surv-T34A-conditioned medium were
analysed at the indicated time intervals for reactivity with antibodies for
caspase-2, caspase-3, caspase-7, caspase-9, PARP, and GAPDH (loading
control) by western blotting. Molecular weight (Mr) markers in kilodaltons
are shown on the left. Densitometric analysis was conducted on caspase-2,
caspase-7, and caspase-9 with their densities as compared to GAPDH
located below each blot. (C) Mitochondrial depolarisation. The experi-
mental conditions are the same as in B, except that HeLa cells grown in
Surv-WT- or Surv-T34A-conditioned medium were analysed at the
indicated time intervals using the mitochondrial membrane potential
monitoring agent JC-1. A reduction in Dcm results in diffusion of the dye
from the mitochondria and a subsequent reduction in the mean red
fluorescent intensity, which is quantifiable using flow cytometry. Stauro-
sporine treatment for 6h is used as a positive control. Data are the
mean±s.e. of two independent experiments.
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sCD11c on leukocytes (Mera et al, 2008), we hypothesised that it
may also modulate the invasive capabilities of cancer cells. In our
hands Surv-WT-CM stimulated a 3- to 4-fold increase in collagen
invasion in comparison with the control medium alone or medium
containing Surv-T34A. Medium depleted of survivin using
antibodies first that recognised the fusion proteins Flag and HA
and then one and three rounds of anti-survivin antibody depletion,
completely inhibited survivin-induced collagen invasion thus
placing survivin as a central player in this increased metastatic
potential.
Stress-induced cancer cell death by means of apoptosis,
necrosis, and autophagy occurs continually during tumour
development and progression (Fonseca and Dranoff, 2008). What
the ramifications of this to the tumour microenvironment is only
beginning to be evaluated. It is believed that the capture of
apoptotic cells serves as an immunoregulatory event that helps
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pretreatment in the conditioned medium. Data are representative of one of two independent experiments with comparable results.
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smaintain tolerance whereas necrotic cells evoke an inflammatory
cascade that mobilises effector responses. On the basis of our
findings, we postulate that many of these released cancer antigens
could in addition to modulating immune function prime the cells
within the tumour microenvironment for the phenotypes asso-
ciated with tumour invasion and metastasis that are listed above.
Survivin expression in CM was measured extracellularly using
ELISA. It is not known whether extracellular survivin originates
from dead cells or is the subject of active secretion. Comparing
s u r v i v i nq u a n t i t yf r o m1t o1 0 %l y s a t e st ot h a to fC Ma r g u e sf o r
active secretion rather than necrosis as SaOS2, Capan1, and HeLa-S-
Surv-WT cells all have equal or more survivin protein but yet have
no dead or dying cells as determined visually and by Trypan blue
exclusion. Importantly, survivin found extracellularly creates a more
erosive disease in patients with rheumatoid arthritis (Bokarewa et al,
2005) and in our cancer cell culture models, parameters that are
considered clinically unfavourable in cancer patients: proliferative
advantage, enhanced resistance to therapy, and enhanced metastatic
potential. Investigating recombinant survivin’s ability to recapitulate
the effects recorded using CM-containing survivin proved unpro-
fitable. From these experiments, we conclude that the survivin
recombinant protein, which has been severed from its GST handle, is
unable to induce similar phenotypes as the CM-containing survivin
as it is unable to enter the cancer cells. Further studies using circular
dichroism mass spectrometry will be required to compare these two
forms of survivin to define differences in structure and or
posttranslational modifications that may aid survivin in binding
with its yet to be defined receptor or trafficking proteins.
A deeper understanding of the mechanisms underlying this
extracellular pool of survivin, the possible ramifications for
tumourigenesis, and the possibility of exploiting it for therapy
are only a few of the many properties of this most fascinating of
proteins that we are continuing to evaluate.
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Figure 9 Effect of Surv-WT and Surv-T34A on tumour cell invasion.
HeLa cells (1 10
5 cells) were seeded into the upper well of the FIA
chamber in 100ml culture medium. Cells were treated with the presence of
Surv-WT- or Surv-T34A-conditioned medium, medium depleted of
survivin using two rounds of fusion protein antibodies (anti-Flag and anti-
HA) and one or three rounds of survivin antibodies in the lower chamber
and incubated at 371C in an atmosphere of 5% CO2. After 24h of
incubation, we lysed and quantitatively analysed fluorescence intensity of
invasive cells that passed through the collagen layer onto the surface of the
fluorescence-blocking membrane, giving relative fluorescent units (RFU).
Data are the mean±s.d. of four independent experiments (*Po0.01).
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